PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

You state "completely ridiculous"
That may seem like a persuasive argument but it lacks any evidence whatsoever.
Logically, while FDA denied sale of Sucanon as a supplement in the US, they stated directly that Sucanon is a drug per the food and drug act, and further cited previous Sucanon studies calling them "substantial clinical investigations". Just as Sucanon would need approval of an investigational new drug application to be sold in the US, so too would "NewMet", the gi active form of metformin under study by the company I referenced and posted a link. You see, their product is not FDA approved, yet it has a potential to retain the effectiveness of the current method of delivery of metformin with lower doses, lower systemic absorption, thus less side effects, and perhaps greater tolerability in patients with renal impairment.
Given that Sucanon outperformed metformin in preclinical testing in rat muscle and has outperformed Glyburide in double blind placebo controlled trial of 370 individuals over 6 months, with no adverse side effects and slight weight loss, there is a reasonable chance that Sucanon may show similar promise to NewMet. Confirmation of that hypothesis would require results of head to head testing of Sucanon and metformin.
If that comparison is favorable, one only need to look at the status of the company that has NewMet under study to get some idea of the potential and the interest that Sucanon would garner from potential drug company partners.
So there is my evidence and rationale. Any may evaluate as they wish...